SARS-CoV-2 Vaccination and Neuroimmunological Disease

Authors:

Abstract
Infection with SARS-CoV-2 results in COVID-19 in many, which can be severe in some. After a year of variable worldwide government-mandated social restrictions, the arrival in 2021 of vaccines against SARS-CoV-2 was very welcome. These used new medical technologies, and there was public and medical concern about any potential serious neurological adverse effects that might occur. As a result, passive and active academic and international clinical surveillance systems focused on public reassurance and ensuring pharmacological safety. The neurological diseases of concern, including specific adverse events of special interest, are all individually rare. Most occur with a background incidence of naturally occurring disease recorded with variable accuracy in nonpandemic historical cohorts. Furthermore, a heterogeneity of ascertainment, recording, and coding strategies have hampered efforts to identify or refute causality. The reporting systems in place are by necessity usually passive, with variable ability to corroborate reports and clean data. Rarely, reliable active ascertainment methods can generate more accurate data.1 In general, evidence that vaccination is causally significant in the pathogenesis of autoimmune neurological syndromes is rarely validated even by large, well-conducted epidemiological studies.2 An almost unique exception to this is the cerebral venous sinus thrombosis, now termed vaccine-associated immune thrombosis and thrombocytopenia (VITT), identified as a rare and specific complication of the adenoviral vector (AV) ChAdOx1 (Oxford/AstraZeneca) and Ad26.COV2.S (Janssen) vaccines.3,4 An increased risk of developing other neurological autoimmune disorders has been extensively sought, but only the very low incidence of Guillain-Barré syndrome (GBS) following AV vaccine administration has been supported by significant evidence.

This publication has 39 references indexed in Scilit: